








key: cord-354702-hi4nxf67
authors: Laszkowska, Monika; Faye, Adam S.; Kim, Judith; Truong, Han; Silver, Elisabeth R.; Ingram, Myles; May, Benjamin; Ascherman, Benjamin; Bartram, Logan; Zucker, Jason; Sobieszczyk, Magdalena E.; Abrams, Julian A.; Lebwohl, Benjamin; Freedberg, Daniel E.; Hur, Chin
title: Disease Course and Outcomes of COVID-19 Among Hospitalized Patients with Gastrointestinal Manifestations
date: 2020-09-30
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2020.09.037
sha: 
doc_id: 354702
cord_uid: hi4nxf67

Background & Aims Our understanding of outcomes and disease time course of COVID-19 in patients with gastrointestinal (GI) symptoms remains limited. In this study we characterize the disease course and severity of COVID-19 among hospitalized patients with gastrointestinal manifestations in a large, diverse cohort from the Unites States. Methods This retrospective study evaluated hospitalized individuals with COVID-19 between March 11 and April 28, 2020 at two affiliated hospitals in New York City. We evaluated the association between GI symptoms and death, and also explored disease duration, from symptom onset to death or discharge. Results Of 2,804 patients hospitalized with COVID-19, the 1,084 (38.7%) patients with GI symptoms were younger (aOR for age≥75 0.59, 95% CI 0.45-0.77) and had more co-morbidities (aOR for modified Charlson comorbidity score ≥2 1.22, 95% CI 1.01-1.48) compared to those without GI symptoms. Individuals with GI symptoms had better outcomes, with a lower likelihood of intubation (aHR 0.66, 95% CI 0.55-0.79) and death (aHR 0.71, 95% CI 0.59-0.87), after adjusting for clinical factors. These patients had a longer median disease course from symptom onset to discharge (13.8 vs. 10.8 days, log-rank p=0.048; among 769 survivors with available symptom onset time), which was driven by longer time from symptom onset to hospitalization (7.4 vs. 5.4 days, log-rank p<0.01). Conclusion Hospitalized patients with GI manifestations of COVID-19 have a reduced risk of intubation and death, but may have a longer overall disease course driven by duration of symptoms prior to hospitalization.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the viral pathogen responsible for causing coronavirus disease 2019 (COVID- 19) , a pandemic that has spread rapidly, infecting over 14 million people globally and causing over 600,000 deaths to date. 1, 2 While the hallmark of this infection is severe respiratory illness, involvement of other organ systems, including the gastrointestinal tract, has been documented. Reports have been mixed, showing anywhere from 11 to 63% of hospitalized patients have at least one gastrointestinal (GI) symptom. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Furthermore, SARS-CoV-2 nucleic acid has been identified in stool samples and on endoscopic biopsies, and absorptive enterocytes in the ileum and colon have been found to highly express Angiotensin Converting Enzyme 2 receptors, which are critical for viral cell entry. [13] [14] [15] [16] [17] [18] [19] These findings indicate that the GI system may be a route for transmission and a moderator of both symptom manifestation and outcomes.

Nonetheless, our understanding of the prognostic implications of GI manifestations, particularly diarrhea, on outcomes has been inconsistent. 20 Some studies suggest gastrointestinal symptoms may convey increased risk of poor outcomes, 4, 21 while others show no association or a potential protective association. [6] [7] [8] [9] These studies vary in their inclusion criteria, ascertainment of GI symptoms, and definitions of severity of disease course. 18, 22, 23 A recent case-control study from our center showed that patients hospitalized with GI manifestations had lower rates of death and were more likely to have a length of stay over 1

week; however, like other early reports of GI symptoms, it did not account for the potential impact of factors such as age and comorbidities on mortality, and did not assess the overall time course of disease from symptom onset to death or discharge. [6] [7] [8] [9] Most reports on outcomes J o u r n a l P r e -p r o o f globally have assessed the impact of GI symptoms on incidence of severe disease, rather than mortality. 4, 21 Furthermore, small studies from China have assessed how time-course of disease is impacted by presence of gastrointestinal symptoms, and some suggest presence of diarrhea may be associated with prolonged symptoms. 4, 11, 19, 24 Here, we aimed to further characterize the duration and severity of COVID-19 among hospitalized patients with gastrointestinal manifestations in a large, diverse cohort from New York City. We hypothesized that the presence of gastrointestinal symptoms could portend a milder disease phenotype, but longer disease time course, potentially due to differences in inflammatory response.

This retrospective study at two affiliated academic hospitals (Columbia University Irving Medical Center, Allen Hospital) includes consecutive hospitalized patients who underwent testing for COVID-19 from March 11, 2020 (when institution-based testing began) to April 28, 2020, and includes a small percentage of patients described in our center's prior report (<8%). 6 

Demographic data, clinical symptoms, laboratory findings, comorbidities, treatment, and outcome data were collected from electronic medical records. Data on symptoms at the time of presentation were obtained using natural language processing algorithms applied to chart documentation, implemented in Python. Presence and absence of various iterations of specific symptoms including fever, fatigue, dizziness, headache, cough, sore throat, congestion, rhinorrhea, shortness of breath, nausea, vomiting, diarrhea, and abdominal pain were systematically identified in emergency room evaluation and admission notes, including in the history of present illness, chief complaint, review of systems, and assessment. The algorithm parsed relevant full text notes and was systematically refined based on chart review to include variations on spelling and phrasing of individual symptom keywords to ensure accurate capture of data. Algorithm extraction was then validated by investigators blinded to the outcomes of the study, who performed manual review of 1,053 charts of the total 2,804 COVID-19 positive patients. Data for symptom documentation between algorithm extraction and manual review was >90% concordant for individual GI symptoms. Exposure to COVID-19 treatments during the J o u r n a l P r e -p r o o f course of the hospitalization were also recorded, including steroids (prednisone, methylprednisolone, and dexamethasone), hydroxychloroquine, azithromycin, remdesivir, and tocilizumab. Patients were considered exposed if they received at least one dose of a given treatment.

Continuous variables were expressed as medians and interquartile ranges, with Wilcoxon rank-sum test used to assess differences in distributions between the groups. Categorical variables were summarized as counts and percentages, with Chi-square or Fisher's exact tests used for comparison. Univariable and multivariable regression analyses were done to compare characteristics of patients with and without GI symptoms in COVID-19. A modified Charlson comorbidity index was utilized in multivariable models, which incorporated weighted values of all components of the index (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, diabetes mellitus, chronic kidney disease, hemiplegia, leukemia, lymphoma, solid tumor, liver disease, and AIDS) but excluded age since it was included separately in our model. Cox proportional hazard models were used to assess the association between gastrointestinal symptoms and 30-day rate of intubation and death, adjusting for age, sex, body mass index, co-morbidities, and presence of respiratory and constitutional symptoms. In a subgroup of patients with available data on timing of symptom onset, Kaplan-Meier analysis was used to assess overall duration of illness, as well as time from symptom onset to admission and time from admission to discharge or death, stratified by the presence of GI symptoms. Patients with unknown symptom onset time as well as one outlier with a reported J o u r n a l P r e -p r o o f symptom duration over 3 months were excluded for this part of the analysis. Symptom onset prior to hospitalization was censored at 14 days to limit recall bias and ensure symptoms were likely associated with having COVID-19. For all analyses, an alpha of 0.05 was considered statistically significant, with calculations performed in STATA 16 (Stata Corp, College Station, TX). This study was approved by the Institutional Review Board of Columbia University Medical Center.

From March 11 th to April 28 th , there were a total of 4,670 individuals who were hospitalized and tested for the SARS-CoV-2 virus, including 2,804 (60.0%) who tested positive.

Among these, 1,084 (38.7%) reported any gastrointestinal (GI) symptoms on presentation, including diarrhea (n=657, 23.4%), nausea/vomiting (n=648, 23.2%), and abdominal pain (n=334, 11.9%; Supplemental Table 1 ).

On univariable analysis ( Table 1) , patients with GI symptoms were more likely to be younger (p<0.01) and have a higher BMI (p<0.01), though there were no significant differences in sex/gender (p=0.18), race/ethnicity (p=0.63), or in underlying comorbidities, other than a slightly higher proportion of patients with a history of stroke presenting without GI symptoms (9% compared to 6%, p=0.01; all other p values>0.05). More patients with GI symptoms had diverticular disease compared to those without (2% compared to 0.5%, p<0.01), though there was no difference among individuals with inflammatory bowel disease or irritable bowel syndrome on univariable analysis. On multivariable analysis ( Table 2) , age ≥75 years (aOR 0.59, p<0.01) was associated with a lower odds of GI symptoms at presentation, whereas an increased number of co-morbidities (aOR 1.22, p=0.04 for modified Charlson comorbidity score J o u r n a l P r e -p r o o f ≥2) was associated with a higher odds of having GI symptoms at presentation. Furthermore, presence of an underlying GI disease including diverticular disease, irritable bowel syndrome, and inflammatory bowel disease was associated with a significantly higher odds of presenting with GI symptoms (aOR 3.04, p<0.01). Male sex (p=0.08) and BMI (all p values>0.49) were not associated with GI symptoms at presentation on multivariable analysis. Of note, some of these differences such as extent of lymphopenia probably have limited clinical relevance despite being statistically significant.

Patients presenting with GI symptoms had better outcomes than those without GI symptoms, including significantly lower rates of intubation (17% vs. 22%, p<0.01) and lower rates of death (15% vs. 23%, p<0.01; Table 1 ). On Kaplan-Meier survival analysis, those presenting with gastrointestinal symptoms had a significantly longer median time to death (7.5 vs. 4.9 days, p<0.01) and lower rate of death than those without (log-rank p<0.01; Figure 1 ).

This persisted on Cox proportional hazards analysis (aHR 0.71, p<0.01; Table 3 Table 2 ).

Next, we explored whether the presence of GI symptoms was associated with differences in disease time course among 945 COVID-19 patients with known symptom onset time. We conducted a time to event analysis looking at how the duration of time between symptom onset and discharge varied. Those who survived (n=769) with GI symptoms had a significantly longer median disease course than those surviving without GI symptoms (13.8 vs. 10.8 days respectively, log-rank p=0.048; Figure 2A) . This was largely driven by longer median time from symptom onset to admission (7.4 vs. 5.4 days, log-rank p<0.01; Figure 2B ), rather than median length of stay (5.7 vs. 4.8 days, log-rank p=0.25; Figure 2C ). Although patients with GI symptoms who died also had a longer course of disease as compared to patients without GI symptoms who died, the result was not statistically significant (13.5 vs. 9.1 days, p-value=0.08).

In this study, we found that hospitalized individuals with COVID-19 who presented with gastrointestinal symptoms of diarrhea, nausea, vomiting, or abdominal pain were younger but had more co-morbidities than those presenting without GI symptoms. Individuals with GI symptoms had better outcomes than those without GI symptoms, including lower rates of intubation and death, even after adjusting for other relevant predictors such as age and comorbidities on multivariable analysis. Patients with GI symptoms also had a longer time-course of disease from symptom onset to discharge, which was largely driven by longer pre-hospital duration (from symptom onset to admission) rather than length of stay.

One possible explanation for this longer but more indolent disease course in individuals with GI symptoms is that such patients may have less systemic inflammation secondary to COVID-19. We demonstrated that patients with GI symptoms had lower inflammatory markers on laboratory testing, including significantly lower C-reactive protein, D-Dimer, and lactate dehydrogenase, and trends towards lower erythrocyte sedimentation rates. These individuals were also less likely to have a leukocytosis. While further research is needed to elucidate the role of specific biomarkers in predicting severity of disease, we hypothesize that a lower degree of inflammation may modulate rates of adverse outcomes such as intubation and death, but the impaired immune response may result in a longer time to clear the virus, resulting in prolonged duration of illness. In contrast, some prior studies have suggested gastrointestinal symptoms may convey increased risk of poor outcomes. 4, 21 This discordance in findings may be due to differences in inclusion criteria, small size of prior studies, as well as differences in the symptoms that were assessed. For example, a study by Wan et al only assessed the impact of diarrhea, but not other gastrointestinal symptoms. 21 Furthermore, patients were admitted with symptoms such as fever, cough, or dyspnea or CT scan abnormalities, but not necessarily a requirement for supplemental oxygen which was included in admission criteria at our institution during the height of the pandemic. Data regarding inflammatory markers corresponding to gastrointestinal symptoms have also been discordant. As such, individuals with diarrhea in the study by Wan et al (n=84) had higher ESR but no difference in CRP or D-Dimer, whereas no difference in inflammatory markers was seen in a small US study by Redd et al (n=318) . 7, 21 It is possible that we were able to detect this difference given the larger size of our study.

Additionally, in this study we demonstrated that individuals with GI symptoms have a longer disease course, which is largely driven by the duration of symptoms prior to J o u r n a l P r e -p r o o f hospitalization. While this may raise concerns about a delayed diagnosis of disease in this population, the fact that they have better outcome suggests that GI symptoms may instead be a marker of more indolent disease, or disease more localized to the GI tract. While these individuals may not need to present earlier for admission, it may be important to recognize and test them early in their disease course given concerns of potential outpatient fecal transmission and infectious spread. 25, 26 In addition, other studies have shown more familial clustering of disease among individuals with GI symptoms. 4 This further emphasizes the importance of early recognition and testing in this population, which remains symptomatic at home longer, to limit spread.

To date, this is the largest study in the US to assess outcomes in COVID-19 positive patients with GI symptoms. Our findings complement the findings of several other recent publications. A prior case-control study from our institution suggested that patients hospitalized with diarrhea, nausea, and vomiting had lower rates of death. 6 Another study from a large center in New York City found that individuals with GI symptoms of diarrhea, abdominal pain, and nausea/vomiting had significantly lower rates of death on univariable analysis (but not on multivariable analysis, though this analysis was for the composite outcome of intensive care unit admission and death). 8 Studies from China have also shown that patients with digestive symptoms have a longer time of symptom onset to admission, and have a longer duration between symptom onset and viral clearance, supporting our findings. 24 Notably, other studies have reported conflicting implications of GI manifestations for disease severity. Inconsistencies in these reports are likely due to the heterogenous nature in which gastrointestinal manifestations and disease severity have been defined and ascertained. 7, 9, 23 For example, studies may have been J o u r n a l P r e -p r o o f confounded by use of antivirals with gastrointestinal side effects, and many utilized different variations of composite outcomes without examining mortality specifically. 4, 21 Our study has many strengths. First, it is the largest study characterizing outcomes in individuals with GI manifestations of COVID-19. We utilized a large dataset from an academic institution at the epicenter of the COVID-19 pandemic in New York City, which represents a diverse population with robust data across many demographic and clinical variables. This is the first study to assess the impact of gastrointestinal symptoms on mortality after adjusting for other relevant clinical factors such as age and comorbidities. Furthermore, this study was the first to document the timeline from symptom onset to hospitalization in a US cohort. These data provide key insights into the clinical presentation of an indolent phenotype of disease, and further research to understand the mechanisms driving this phenotype will help identify those at highest risk for complications of this disease.

Our study does have limitations. First, symptom reporting is limited by recall bias of individual patients, as well as ascertainment bias among providers. To mitigate this, we utilized a natural language processing algorithm to flag symptom reporting across provider documentation between diarrhea and severe outcomes. In addition, details regarding attributes of specific symptoms, such as frequency and consistency of diarrhea, were not reliably recorded which is a limitation of the data. Another limitation is that this analysis only involved hospitalized patients.

Further research of outpatients with and without GI manifestation may give additional insights into the broader population afflicted with COVID-19. Finally, our analysis did not account for impact of various investigational treatments on outcome.

In conclusion, our study demonstrates that individuals with gastrointestinal symptoms including diarrhea, nausea, vomiting, and abdominal pain have lower rates of intubation and death than those without GI symptoms. These individuals have a more indolent disease course, driven largely by longer time from symptom onset to admission. Given the lower inflammatory marker profiles in these patients, it is possible that GI manifestations convey a phenotype of disease with a dampened immune response -potentially improving outcomes but delaying viral clearance. Further research is needed to better understand the mechanisms underlying these differences, which may lead to an improved understanding of the natural history and time course of COVID-19. 

COVID-19 Dashboard

World Health Organization Coronavirus disease 2019 (COVID-19) Situation Report -51

Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study

Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms

Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)

Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States

Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study

Gastrointestinal and Hepatic Manifestations of

Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications

High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California

Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Don't Overlook Digestive Symptoms in Patients With 2019 Novel Coronavirus Disease (COVID-19)

Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process

COVID-19 and the gastrointestinal tract: more than meets the eye

First Case of 2019 Novel Coronavirus in the United States

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Evidence for Gastrointestinal Infection of SARS-CoV-2

Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus

Diarrhea Is Associated With Prolonged Symptoms and Viral Carriage in Corona Virus Disease

Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management

Enteric involvement in hospitalised patients with COVID-19 outside Wuhan

COVID-19 in gastroenterology: a clinical perspective

Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Internal and Emergency Medicine

Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. The American journal of gastroenterology

Transmission of SARS-CoV-2 via fecal-oral and aerosols-borne routes: Environmental dynamics and implications for wastewater management in underprivileged societies

Sewage monitoring is the UK's next defence against covid-19

J o u r n a l P r e -p r o o f 

